Case Report
                                    The role of rivaroxaban in left ventricular thrombi
                                    
                                    
                                                                                                                                    1Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, University of Alexandria; Alexandria-Egypt
2Department of Cardiology, Faculty of Medicine, University of Alexandria; Alexandria-Egypt
3Department of Internal Medicine, Michigan State University; East Lansing, Michigan-United States of America
4Department of Cardiology, Massachusetts General Hospital; Boston-United States of America
5Department of Cardiology, Ain Shams University; Cairo-Egypt
                                                                                                                        
                                    
                                2Department of Cardiology, Faculty of Medicine, University of Alexandria; Alexandria-Egypt
3Department of Internal Medicine, Michigan State University; East Lansing, Michigan-United States of America
4Department of Cardiology, Massachusetts General Hospital; Boston-United States of America
5Department of Cardiology, Ain Shams University; Cairo-Egypt
                                                                            Keywords: Left ventricular apical thrombi, Novel Oral Anticoagulants (NOACs), Rivaroxaban, Vitamin K Antagonist (VKA), Acute Coronary Syndromes (ACS), Dual Antiplatelet Therapy (DAPT)